Overview

• US medical technology firm's fiscal Q4 sales rose 8%, beating analyst expectations

• Adjusted EPS and adjusted net income for Q4 beat analyst estimates, but both remained negative

• Quarterly growth driven by Med Tech segment, with strong NanoKnife and Auryon sales

Outlook

• AngioDynamics sees fiscal 2027 net sales between $336 mln and $341 mln

• Company expects Med Tech net sales growth of 12%–15% and Med Device net sales growth flat

• AngioDynamics expects gross margin of 54%–55% and adjusted EBITDA of $13 mln–$16 mln for fiscal 2027

Result Drivers

• NANOKNIFE GROWTH - NanoKnife sales rose 64.5% in Q4, driven by 47% growth in probes and 132.5% growth in capital sales, supported by new reimbursement milestones and positive clinical data

• AURYON PLATFORM - Auryon sales increased 14.4% year-over-year, contributing to Med Tech segment growth

• GROSS MARGIN IMPROVEMENT - Gross margin rose 130 basis points to 54.0%, mainly due to favorable pricing and a shift toward higher-margin Med Tech products

Company press release: ID:nBwLkbVSa

Key Details

Metric	Beat/Miss	Actual	Consensus Estimate
Q4 Sales	Beat	$86.60 mln	$80.40 mln (3 Analysts)
Q4 Adjusted EPS	Beat	-$0.07	-$0.09 (3 Analysts)
Q4 Adjusted Net Income	Beat	-$2.80 mln	-$3.82 mln (3 Analysts)
Q4 Net Income		-$11.40 mln

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

• Wall Street's median 12-month price target for AngioDynamics Inc is $16.00, about 25.2% above its July 13 closing price of $12.78

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.